PIK3CB and melanoma: The inhibition of ERK has been evaluated as treatment alone or in combination with other drugs, both in the same MAPK pathway and associated with the suppression of parallel pathways such as PI3K, since ERK inhibition could cause a paradox RAS and PI3K activation which can lead to melanoma resistance [100,101,102].